Eylea (aflibercept)has been approved by the FDA to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older by gradually destroys a person’s sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving, as well as being able to read or recognize people’s faces.
Continue reading on Examiner.com Eylea approved to treat wet age-related macular degeneration – Hartford wellness | Examiner.com http://www.examiner.com/wellness-in-hartford/eylea-approved-to-treat-wet-age-related-macular-degeneration#ixzz1fi2V8QxC
Advertisement
